Author | Year | Type of study | FIGO Stage | Median age (exp/ctr) | Patients (exp/ctr) | Treatment | HR (95% CI) | ||
---|---|---|---|---|---|---|---|---|---|
RT doses | CT regimens | OS | PFS | ||||||
Alfonso [23] | 2005 | Prospective | IB2–IIB | 41/49 | 43/40 | EBRT 50 Gy + BT 30–35 Gy if high risk factors | Cisplatin + GEM/ cisplatin | 0.18 (0.01–3.80) | 0.17 (0.02–1.49) |
Veerasarn [15] | 2007 | Prospective | IIB–IVA | 49.6/49.7 | 234/235 | EBRT 40–50 Gy/20–25 F + ICRT | Tegafur-uracil + carboplatin/carboplatin | 0.90 (0.52–1.56) | |
Peter [18] | 2007 | Prospective | IIB–III | NR | 176/173 | EBRT 40.8–51 Gy + BT 30–40 Gy | Cisplatin + 5-FU + HU/ cisplatin | 0.90 (0.59–1.38) | 0.99 (0.65–1.51) |
Kim [21] | 2008 | Prospective | IIB–IVA | 60/57 | 79/79 | EBRT 41.4–50.4 Gy/23–28 F + ICRT 30–35 Gy/6–7 F | 5-FU + cisplatin/ cisplatin | 0.98 (0.47–2.04) | 1.28 (0.68–2.41) |
Torres [16] | 2008 | Prospective | III–IV | NR | 191/111 | EBRT 45 Gy (most pts) + LDR BT (most pts) | Cisplatin + 5-FU / cisplatin | 0.42 (0.25–0.69) | |
Alfonso [22] | 2011 | Prospective | IIB–IVA | 45/46 | 259/256 | EBRT 50.4 Gy/28 F + ICRT 30 Gy/6 F | GEM + cisplatin/ cisplatin | 0.68 (0.49–0.95) | 0.68 (0.49–0.95) |
Nedovic [12] | 2012 | Retrospective | IIB–IVA | 51/54 | 64/70 | EBRT 50.4–54 Gy/20–30 F + ICRT 30–34 Gy/5 F | 5-FU + cisplatin/ cisplatin | 0.66 (0.34–1.28) | 0.68 (0.37–0.99) |
Tang [13] | 2012 | Retrospective | IIB–IVA | 53/57 | 440/440 | EBRT 48–50 Gy/24–25F + ICRT 24 Gy/4 F | PAC + cisplatin/ cisplatin | 0.76 (0.56–1.04) | 0.62 (0.48–0.80) |
Donnelly [10] | 2013 | Retrospective | IB1–IVA | NR | 42/95 | EBRT 51.42 + LDR-BT | Cisplatin + 5-FU/ cisplatin | 0.85 (0.38–1.92) | 0.84 (0.39–1.83) |
Lee [11] | 2013 | Retrospective | IB–IIA | 45.5/44.5 | 21/34 | EBRT 50.4 Gy (BT not done) | Cisplatin + CTX or cisplatin + 5-FU or carboplatin + 5-FU or carboplatin + PAC/ cisplatin | 0.78 (0.17–3.51) | 0.26 (0.07–0.95) |
Pu [19] | 2013 | Prospective | IB–IIA | 47/45 | 145/140 | EBRT 46–54 Gy + BT 24 Gy | Cisplatin + DOC/ cisplatin | 0.65 (0.39–1.09) | 0.64 (0.40–1.03) |
Wang [8] | 2015 | Prospective | III–IVA | 55/56 | 37/37 | EBRT 45 Gy/25 F + ICRT 25.8 Gy/6 F | GEM + cisplatin/ cisplatin | 0.93 (0.35–2.47) | 0.86 (0.39–1.91) |
Li [20] | 2015 | Prospective | IIB–IVA | 51.7/49.8 | 36/36 | EBRT 50 Gy/25 F + ICRT 10 Gy/2 F | S-1 + cisplatin/ cisplatin | 0.86 (0.32–2.31) | 0.89 (0.28–2.71) |
Thakur [17] | 2016 | Prospective | IIA–IIIB | NR | 39/42 | EBRT 50 Gy/25 F + ICRT 10 Gy/3 F | PAC + cisplatin/ cisplatin | 0.54 (0.18–1.61) | 0.47 (0.20–1.09) |
Zhao [14] | 2016 | Retrospective | IA2–MIIB | 50/52 | 75/71 | EBRT 46–50 Gy/23–25 F + BT 30 Gy/ 5F | PAC + cisplatin consolidation/PAC + cisplatin | 0.70 (0.31–1.60) | 0.80 (0.38–1.67) |
Samantha [24] | 2019 | Prospective | IIB–IVA | 48/45 | 55/52 | EBRT 45 Gy/25–28 F + BT 28–30 Gy/4–5 F | Cisplatin + GEM/ cisplatin | 2.79 (1.29–6.01) | 1.84 (1.04–3.26) |
Siriwan [4] | 2019 | Prospective | IIB–IVA | 49/50 | 130/129 | EBRT 54 Gy + ICRT 28 Gy | Cisplatin + carboplatin + PAC/ cisplatin | 1.42 (0.81–2.49) | 1.26 (0.82–1.96) |